Aussie first hits lucrative market
Roche could be set to disrupt a lucrative market with the launch of Australia's first continuous drug-delivery system for neovascular (wet) age-related macular degeneration (nAMD), following TGA approval of the company's Susvimo for use with the already approved Contivue ocular implant.
To see the whole article, log in or create an account.